Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...

Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

The top 25 stocks in the S&P 500 by weight are the largest, most influential companies in the index. The S&P 500 is widely considered to be one of the best measures of stock market performance and ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...